JP5010125B2 - Film preparation for athlete's foot treatment - Google Patents
Film preparation for athlete's foot treatment Download PDFInfo
- Publication number
- JP5010125B2 JP5010125B2 JP2005254415A JP2005254415A JP5010125B2 JP 5010125 B2 JP5010125 B2 JP 5010125B2 JP 2005254415 A JP2005254415 A JP 2005254415A JP 2005254415 A JP2005254415 A JP 2005254415A JP 5010125 B2 JP5010125 B2 JP 5010125B2
- Authority
- JP
- Japan
- Prior art keywords
- athlete
- foot
- oil
- acid
- ringworm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
この発明は、水虫の予防と治療を目的としたフィルム製剤に関するものである。 The present invention relates to a film preparation for the purpose of prevention and treatment of athlete's foot.
水虫は、白癬菌(皮膚糸状菌)というカビの一種によって起こる皮膚の病気である。
この白癬菌は、皮膚の一番外側にある角質層に寄生して増殖していく。白癬菌が増殖する条件には、えさが豊富なことと高温多湿の二つがある。
一つ目の白癬菌のエサとなるのは、垢となって落ちる角質であり、手と足が最も角質層が厚くなっている。手は洗うことが多く、乾燥しているため、白癬菌がつくことはあまりないが、足は白癬菌が付きやすい状態である。
二つ目の高温多湿はカビの一種である白癬菌が活性化する状態にある。一般的に温度が15℃以上、湿度が70%以上になると活性化するといわれている。従って、汗をかいたり、靴の中が高温になる春から夏にかけて、白癬菌は増殖する。反対に低温で乾燥している冬は、白癬菌は増えにくく、休眠状態となる。
Athlete's foot is a skin disease caused by a kind of mold called ringworm fungus (dermatophyte).
The ringworm bacteria grow in a parasitic manner on the outermost stratum corneum of the skin. There are two conditions for the growth of ringworms: rich food and high temperature and humidity.
The first thing that feeds the ringworm is the keratin that falls in the form of dirt, and the stratum corneum is thickest in the hands and feet. Hands are often washed and dry, so it is unlikely to cause ringworm bacteria, but feet are likely to have ringworm bacteria.
The second high temperature and high humidity activates ringworm, a kind of mold. In general, it is said that activation occurs when the temperature is 15 ° C. or higher and the humidity is 70% or higher. Therefore, ringworms grow from spring to summer when sweating and the inside of shoes is hot. On the other hand, in winter when it is dry at low temperature, ringworm bacteria are hard to increase and become dormant.
家庭内の白癬菌の感染経路としては、スリッパやバスマットなどが考えられる。水虫の患者が使用したスリッパやバスマットに皮膚の破片が落ちていると、破片の中で生き残っている白癬菌が、他の人の足に付き、すぐに靴下を履いたり、靴を履いたりすると、湿った皮膚に長時間白癬菌が付着することになり、皮膚に白癬菌が入り込んで感染する。
水虫の種類には足にできる足白癬と感染した部位によって体部白癬、股部白癬、頭部白
癬、手白癬、爪白癬などがある。
足白癬のタイプには、次の3つがある。(1)趾間型は指の間の皮が白くなり、赤くただれて皮膚が露出し、ジクジクしていることが多く、他の細菌も付きやすい状態である。 (2)小水泡型は、足の裏や指の付け根に小さな水泡ができ、それが破れて皮がむけて赤くなり、かゆみがでる。(3)角質増殖型は、足裏全体に白癬菌が増殖して角質層が厚くなり、粉を吹いたように皮がむける状態のものである。足白癬以外に足の爪の中に白癬菌が入り込んだ(4)爪白癬がある。
Slippers and bath mats can be considered as infection routes of ringworms in the home. If a piece of skin falls on the slippers or bath mat used by athlete's foot patients, the ringworm that survives in the piece will stick to other people's feet and immediately wear socks or wear shoes. As a result, ringworm bacteria adhere to wet skin for a long time, and ringworm bacteria enter the skin and become infected.
Types of athlete's foot include ringworm on the foot and body ringworm, hip ringworm, head ringworm, hand ringworm, and onychomycosis depending on the infected site.
There are three types of tinea pedis: (1) In the intercostal type, the skin between fingers becomes white, it is reddish, the skin is exposed, and it is often wrinkled, and other bacteria are also easily attached. (2) Small water bubbles form small water bubbles on the soles of the feet and the base of the fingers that tear and turn red and become itchy. (3) The stratum corneum growth type is a state in which ringworm bacteria grow on the entire sole, the stratum corneum becomes thick, and the skin is peeled off like powder. In addition to foot ringworm, ringworm bacteria have entered the toenail (4) nail ringworm.
水虫には薬物治療が行われるが、症状に応じて、外用薬と内服薬が使い分けられる。
趾間型、小水泡型の場合は、白癬菌の増殖を抑制する外用薬を塗布するが再発を防止するために最低1カ月以上は薬剤を塗り続けることが大切である(例えば、特許文献1)。
角質増殖型や爪白癬などは、皮膚の内部や爪の内部までに外用薬の有効成分が届かないために、内服薬が用いられる。内服薬は一般的に半年間は飲み続ける必要がある。
水虫はカビの一種である白癬菌が原因である。カビの感染・増殖の条件を整えないことが、水虫予防にとって大切であるが、湿ったバスマットやスリッパなどの共有によって、一人の水虫患者からや家庭内或いは同じ職場の同僚、共同浴場利用者等に白癬菌が感染するケースが非常に多い。従って、一人の水虫の患者が治療するには家族全員、職場全員、浴場利用者全員の協力を仰ぐ必要があり、完璧な治療には相当の労力と時間と協力がポイントとなるが現実的には非常に厳しい。
In the case of intercostal type and small water bubble type, it is important to apply an external medicine that suppresses the growth of ringworm bacteria, but to keep applying the medicine for at least one month or more in order to prevent recurrence (for example, Patent Document 1) .
For keratoproliferative type and onychomycosis, an internal medicine is used because the active ingredient of the external medicine does not reach the inside of the skin or the inside of the nail. Oral medications generally need to be taken for half a year.
Athlete's foot is caused by the fungus Ringworm. It is important for the prevention of athlete's foot not to prepare conditions for mold infection and growth, but by sharing wet bath mats and slippers, etc., from one athlete's foot patient, at home or in the same workplace, a common bath user, etc. There are very many cases that are infected with ringworm. Therefore, to treat a single athlete's foot patient, it is necessary to ask for the cooperation of the whole family, the workplace, and all the bath users. Is very tough.
水虫の治療には白癬菌の増殖を抑制する外用薬が用いられるが、皮下への薬物の浸透性が悪く、マッサージ等により物理的に多量の薬物を毎日長期(約1カ月以上)に塗り続ける必要がある。
外用薬は皮膚上に塗られたものであり、風呂の習慣性がある日本人にとっては、日々洗い流された外用薬を補充する目的で、風呂上がりに毎日塗布する必要がある。また、入浴時に浴槽内の湯や浴槽を1日前に塗布した薬剤で汚染することが多く、感染を嫌う家族や友人、同じ銭湯を利用する仲間に嫌われるのが一般的である。
また、家庭内或いは職場内での同じバスマットやスリッパ等を共有することによって一人の水虫患者から家族や職場の同僚、更におなじ公衆浴場等を利用する人達に白癬菌が感染する危険性が極めて高く、彼らの協力無しには水虫を完璧に治療することは極めて厳しい現実がある。
For the treatment of athlete's foot, a topical drug that suppresses the growth of ringworm is used, but the penetration of the drug into the skin is poor, and physically a large amount of drug is applied every day for a long time (about 1 month or more) by massage etc. There is a need.
The topical medicine is applied on the skin, and for Japanese people who have the habit of taking a bath, it is necessary to apply the medicine every day after bathing in order to replenish the topical medicine that has been washed away every day. Moreover, hot water in a bathtub or a bath is often contaminated with a chemical applied one day before bathing, and is generally disliked by family members, friends who dislike infection, and friends who use the same public bath.
In addition, by sharing the same bath mat and slippers at home or in the workplace, there is a very high risk of ringworm fungus from a single athlete's foot patient to a family member, a colleague at work, and people using the same public bath. Without their cooperation, it is extremely difficult to treat athlete's foot perfectly.
水虫には、その症状から(1)小水泡型、(2)趾間型、(3)角質増殖型及び(4)爪白癬の4タイプに分類できる。
小水泡型と趾間型は、一般的治療法として外用薬療法が用いられるが、角質増殖型と爪白癬は外用剤を用いても白癬菌がいるところまで薬が浸透していかないために、内服薬による治療が必要になる。
内服薬にはグリセオフルビン、塩酸テルビナフィン、イトラコナゾール等の抗真菌薬が用いられるが、抗真菌薬は真菌の細胞膜に障害を与えて効果を表すが、人間の細胞にも同じ障害を与えるため、それだけ副作用が現れやすい。例えば、グリセオフルビン製剤では、肝機能障害、黄疸、めまい、頭痛、発熱、ねむけ、耳鳴り、精神錯乱、手足のしびれや痛み、味覚障害、視力障害、色素沈着、過敏症以外の発疹、じんましん、男性では女性化乳房等、塩酸テルビナフィン製剤では、貧血、嘔吐、疲労感、発疹、じんましん、かゆみ、関節痛、筋肉痛等、イトコナゾール製剤では肝障害、筋肉痛等の症状に加えて、抗アレルギー剤のテルフェナジン、健胃消化剤のシサプリド製剤、睡眠鎮静剤のトリアゾラン製剤、脂質代謝改善剤のシンバスタチン製剤、免疫抑制剤のシクロスポリン製剤、強心剤のジゴキシン製剤、カルシウム拮抗剤のニフェジピン製剤、ピモジド製剤等と併用すると副作用が起こりやすくなるといった現実がある。
The athlete's foot can be classified into four types: (1) small blister type, (2) intercostal type, (3) stratum corneum type, and (4) nail ringworm.
For small water bubbles and intercostal types, external medicine is used as a general treatment, but for keratinous growth type and onychomycosis, even if external medicine is used, the medicine does not penetrate to the place where ringworm bacteria are present. Treatment with is required.
Antifungal drugs such as griseofulvin, terbinafine hydrochloride, and itraconazole are used for internal use, but the antifungal drugs are effective by damaging the cell membrane of fungi, but they also cause the same damage to human cells, so there are side effects. Easy to appear. For example, with griseofulvin, liver dysfunction, jaundice, dizziness, headache, fever, sleepiness, tinnitus, mental confusion, numbness and pain in the limbs, taste disorder, visual impairment, pigmentation, rash other than hypersensitivity, hives, men In the case of gynecomastia, terbinafine hydrochloride is anemia, vomiting, fatigue, rash, hives, itching, arthralgia, muscle pain, etc. Concomitant use with terfenadine, cisapride formulation for gastrointestinal digestion, triazolane formulation for sleep sedation, simvastatin formulation for lipid metabolism improver, cyclosporine formulation for immunosuppressant, digoxin formulation for cardiotonic agent, nifedipine formulation for calcium antagonist, pimozide formulation, etc. Then, there is a reality that side effects are likely to occur.
そこで、本発明者は、水虫の特徴と現実の治療方法を詳細に検討し、分析してみた。そして、詳細に検討していくうちに、従来の薬剤による治療方法とは大いに異なる新しい製剤による治療方法を確立することが可能となった。
従来の水虫治療法である外用薬による治療方法では、患部に塗布した薬が日常生活の中で入浴や歩く度に床やソックス等への接触により除去されやすいために、効果が減弱されやすく、逆に第三者への白癬菌の媒介の一助となる危険性さえ生じることに気づいた。
また、従来の外用剤では、皮膚内部への薬物の浸透性が悪く、約1カ月以上の再三の塗布回数を要するが、患部を製剤的にODT(密封)することによって、塗布薬物の皮膚への浸透性(経皮吸収性)を改善し、薬剤の塗布量と塗布回数を減らすことによって患者の負担を軽減し、より効率的に治療することができると考えた。 更に、患部をODT(密封)することによって、治療効果の改善に加えて第三者への白癬菌による感染を予防することが可能であることに気づいた。
また、抗真菌剤の経口による治療が必須であった角質増殖型水虫と爪白癬に対しても、ODT療法(密封療法)と角質溶解剤との組み合わせによって、副作用の大きい薬物の内服療法に依存することなく、副作用の少ない外用剤による治療が可能であることを見い出した。
この発明が解決しようとする課題は、水虫の治療を第三者に感染させることなく、外用薬がより効率的に作用し、且つ、副作用のでないようにする水虫治療製剤を提供することにある。
Therefore, the present inventor examined and analyzed in detail the characteristics of athlete's foot and the actual treatment method. As a result of detailed examination, it has become possible to establish a treatment method using a new preparation that is very different from the treatment method using conventional drugs.
In the conventional treatment method with athlete's foot treatment, the drug applied to the affected area is easily removed by contact with the floor or socks every time bathing or walking in daily life. Realized that there was even a risk of helping to infect ringworm bacteria to third parties.
In addition, conventional external preparations have poor drug penetration into the skin and require repeated application times of about one month or more. However, by applying the ODT (sealing) to the affected area, the applied drug can be applied to the skin. We thought that the patient's burden could be reduced by improving the permeability (percutaneous absorbability) of the drug and reducing the amount and the number of times the drug was applied, so that treatment could be performed more efficiently. Furthermore, it has been found that ODT (sealing) of the affected area can prevent infection by third party bacteria in addition to improving the therapeutic effect.
In addition, keratoproliferative type athlete's foot and onychomycosis, which had been required to be treated with oral antifungal agents, depend on oral treatment of drugs with large side effects by combining ODT therapy (sealing therapy) with keratolytic agents. It has been found that treatment with an external preparation with few side effects is possible.
The problem to be solved by the present invention is to provide an athlete's foot treatment preparation that allows the topical medicine to work more efficiently and have no side effects without infecting the third party with athlete's foot treatment. .
発明者は、水虫を第三者に感染させることなく、効率的に且つ副作用の出ないようにするには、どのように治療すればよいかという点について考察し、実験を重ねた。
そして、水虫に感染した患部を外部と遮断するために防水シートで被覆することによるODT効果(密封効果)により、水虫を第三者に感染させることなく、経口投与に頼ることもなく薬物を効率的、且つ、安全に経皮吸収させることに成功した。しかしながら、防水シートを日常生活の中で患部に連続して固定することは非常に困難であった。
そこで発明者は、患部で防水シートに代わるフィルムを形成させることができれば、この使用上の問題点を解決できると考え、フィルム形成目的でニトロセルロースを選択し、酢酸3−メチルブチルとエチルアルコールとの混合液に溶解させたのち皮膚に塗布すると、期待どおり体温で溶解剤が揮散したのち透明なフィルムが形成されるのを確認することができ、発明者は、この事実を基にして研究を重ねた結果、この発明を完成させることができた。
The inventor considered and discussed how to treat the athlete's foot without infecting third parties efficiently and without causing side effects.
And the ODT effect (sealing effect) by covering the affected area infected with athlete's foot with the waterproof sheet to block the outside, without infecting athlete's foot with a third party, and without having to rely on oral administration Has been successfully and safely absorbed through the skin. However, it has been very difficult to continuously fix the waterproof sheet to the affected part in daily life.
Therefore, the inventor thinks that this problem can be solved if a film can be formed to replace the waterproof sheet in the affected area, and nitrocellulose is selected for the purpose of film formation, and 3-methylbutyl acetate and ethyl alcohol are used. When dissolved in a mixed solution and applied to the skin, it can be confirmed that a transparent film is formed after the dissolution agent volatilizes at the body temperature as expected, and the inventor repeated research based on this fact. As a result, the present invention was completed.
本発明に係る水虫治療用フィルム製剤は、前記課題を解決したものであって、次のとおりのものである。
すなわち、請求項1の発明は、ニトロセルロースを、酢酸エチル、酢酸3−メチルブチル、酢酸イソブチル、乳酸エステル、アセトン、或いは、これらの一種類以上を混合した混合物の溶解剤に溶解し、このニトロセルロースの溶解剤に外用薬を溶解して、このニトロセルロースの溶解剤に外用薬を溶解して、前記溶解剤の中には、天然油であるシソオイル、ゴマ油、エゴマ油、オリーブ油、馬油、ヒノキオイル、ひまし油、または、フタル酸エステル、脂肪族多塩基酸エステルの一種類以上を含有させ、膜形成時の膜の強度・柔軟性と密封効果を高めるとともに、更に、エチルアルコール、または、イソプロパノール、或いはこれらの混合物を添加し、前記外用薬として、角質を溶解し有効薬物の治療効果を促進する角質溶解剤であるサリチル酸、尿素、安息香酸の内、一種類以上を含有し、且つ水を含まない製剤としたことを特徴とする水虫治療用フィルム製剤である。
請求項2の発明は、前記外用薬として、水虫の原因菌である白癬菌に対して殺菌或いは抗菌活性を有する抗真菌薬の塩酸ブテナフィン、塩酸テルビナフィン、塩酸ネチコナゾール、塩酸アモロルフィン、硝酸エコナゾール、スティコプスエキス、トルナフテート、ピロールニトリン、クロトリマゾール、蝋梅油、サリチル酸、安息香酸、クエン酸、酢酸、木酢液、竹酢液のうち、一種類以上を含有して水虫の予防と治療をすることを特徴とする請求項1に記載の水虫治療用フィルム製剤である。
請求項3の発明は、前記外用薬として、グリチルリチン酸、グリチルリチン酸ナトリウム、グリチルレチン酸、リドカイン、キシロカイン、クロタミトン、カンフル、l−メントール、ハッカ油の内、一種類以上を含有したものであり、患部のかゆみを抑制することを特徴とする請求項1に記載の水虫治療用フィルム製剤である。
[発明の作用]
The film preparation for athlete's foot treatment according to the present invention solves the above-mentioned problems and is as follows.
That is, in the invention of claim 1, nitrocellulose is dissolved in a dissolving agent of ethyl acetate, 3-methylbutyl acetate, isobutyl acetate, lactic acid ester, acetone, or a mixture of one or more of these, and the nitrocellulose. Dissolve topical medicine in this solubilizer and dissolve the topical medicine in this nitrocellulose solubilizer. Among the solubilizers are natural oils such as perilla oil, sesame oil, sesame oil, olive oil, horse oil, hinoki. oil, castor oil, or phthalic acid ester, is contained one or more aliphatic polybasic acid ester, to increase the sealing effect between strength and flexibility of the film during film formation, further, or ethyl alcohol, Isopuropa Bruno Lumpur, or by adding these mixtures, as the external medicine, a keratolytic agent to facilitate the therapeutic effect of the active drug to dissolve the horny Sari Le acid, urea, among benzoic acid, contain one or more, is for athlete's foot treatment film preparation and is characterized in that the formulation does not contain water.
The invention according to claim 2 is characterized in that the topical drug is an antifungal agent butenafine hydrochloride, terbinafine hydrochloride, neticonazole hydrochloride, amorolfine hydrochloride, econazole nitrate, stico To prevent and treat athlete's foot with one or more of pus extract, tolnaftate, pyrrolnitrin, clotrimazole, waxy plum oil, salicylic acid, benzoic acid, citric acid, acetic acid, wood vinegar, bamboo vinegar The film preparation for athlete's foot treatment according to claim 1.
The invention of claim 3 contains one or more of glycyrrhizic acid, sodium glycyrrhizinate, glycyrrhetinic acid, lidocaine, xylocaine, crotamiton, camphor, l-menthol, and mint oil as the external medicine, The film preparation for athlete's foot treatment according to claim 1, wherein itching is suppressed.
[Effect of the Invention]
この発明に係る水虫治療用フィルム製剤においては、ニトロセルロースを、酢酸エチル、酢酸3−メチルブチル、酢酸イソブチル、乳酸エステル、アセトン、或いは、これらの一種類以上を混合した混合物の溶解剤に溶解し、このニトロセルロースの溶解剤に外用薬を溶解して、このニトロセルロースの溶解剤に外用薬を溶解して、前記溶解剤の中には、天然油であるシソオイル、ゴマ油、エゴマ油、オリーブ油、馬油、ヒノキオイル、ひまし油、または、フタル酸エステル、脂肪族多塩基酸エステルの一種類以上を含有させ、更に、エチルアルコール、または、イソプロノール、或いはこれらの混合物を添加した基剤であって水を含まない製剤としたので、膜形成時の膜の強度・柔軟性と密封効果が高まるとともに、抗真菌薬を加えて、皮膚刺激薬や鎮痒薬を添加したものであり、皮膚に塗布した後溶剤が揮散し、透明或いは半透明のフィルムを皮膚上に形成することにより患部を密封し、真菌の患部からの拡散を予防することによって他者への感染を防ぐことが可能となる。更に、ODT効果(密封効果)によって抗真菌薬の経皮吸収性が向上し、皮膚角質層下部の真菌生息層に薬剤が浸透することによって白癬菌に対する殺菌効果が増強される。 また、溶解剤(酢酸3−メチルブチル、酢酸イソブチル、アセトン、エチルアルコール)自体が殺菌作用及び抗真菌作用を有するために、患部の皮膚に塗布する段階で表在性の雑菌及び真菌に対して殺菌及び抗真菌作用を発揮する。
In the film preparation for athlete's foot treatment according to the present invention, nitrocellulose is dissolved in a dissolving agent of ethyl acetate, 3-methylbutyl acetate, isobutyl acetate, lactate ester, acetone, or a mixture of one or more of these, A topical drug is dissolved in the nitrocellulose solubilizer, and a topical drug is dissolved in the nitrocellulose solubilizer. Among the solubilizers, there are natural oils such as perilla oil, sesame oil, sesame oil, olive oil, horses. oil, cypress oil, castor oil, or phthalic acid ester, is contained one or more aliphatic polybasic acid ester, further, ethyl alcohol, or isopropyl Roh Lumpur, or a in base with the addition of a mixture thereof Te since the formulation without water, with the sealing effect is enhanced as the strength and flexibility of the film during film formation, in addition to anti-fungal agents, skin Adds stimulants and antipruritics, and after application to the skin, the solvent evaporates, forming a transparent or translucent film on the skin to seal the affected area and prevent the spread of fungus from the affected area It is possible to prevent infection to others. Further, the transdermal absorbability of the antifungal agent is improved by the ODT effect (sealing effect), and the bactericidal effect against ringworm fungi is enhanced by the penetration of the drug into the fungal habitat layer below the skin stratum corneum. In addition, since the solubilizer (3-methylbutyl acetate, isobutyl acetate, acetone, ethyl alcohol) itself has a bactericidal action and an antifungal action, it is sterilized against superficial germs and fungi when applied to the affected skin. And exerts an antifungal action.
本発明によれば、ニトロセルロースを、酢酸エチル、酢酸3−メチルブチル、酢酸イソブチル、乳酸エステル、アセトン、或いは、これらの一種類以上を混合した混合物の溶解剤に溶解し、このニトロセルロースの溶解剤に外用薬を溶解して、このニトロセルロースの溶解剤に外用薬を溶解して、前記溶解剤の中には、天然油であるシソオイル、ゴマ油、エゴマ油、オリーブ油、馬油、ヒノキオイル、ひまし油、または、フタル酸エステル、脂肪族多塩基酸エステルの一種類以上を含有させ、更に、エチルアルコール、または、イソプロパノール、或いはこれらの混合物を添加して、水を含まない製剤としたので、ニトロセルロースを主体とした膜形成時の膜の強度・柔軟性と密封効果を高めるとともに、抗真菌剤を加えて皮膚刺激薬や鎮痒薬を配合して製剤としたものであり、皮膚に塗布した後溶剤が揮散し、透明或いは半透明のフィルムを皮膚上に形成することにより、患部を密封し、白癬菌の患部からの拡散を予防することによって他者への感染を防ぐ。更にODT効果(密封効果)によって、抗真菌薬の経皮吸収性を改善し、皮膚角質層下部の白癬菌生息層に抗真菌薬が十分に送達されることによって高い殺菌効果が期待できる。
また、薬剤塗布時に、溶解剤自体が抗真菌作用と殺菌作用を発揮する為に、皮膚表在性の真菌や雑菌に対する殺菌効果を発揮し、治療効果を助長する。
更に、患部に塗布した薬物を被膜で被覆することによって、入浴やシャワーによる薬剤の流出を防止することで効果の持続性が期待でき、更に、膜形成後の製剤が水や温水によって流出することが極めて少ないので、浴槽の水を汚染することがない。
According to the present invention, nitrocellulose is dissolved in a solubilizer of ethyl acetate, 3-methylbutyl acetate, isobutyl acetate, lactate ester, acetone, or a mixture of one or more of these, and this nitrocellulose solubilizer Dissolve the topical medicine in the nitrocellulose solubilizer, and the solubilizer contains natural oils such as perilla oil, sesame oil, sesame oil, olive oil, horse oil, hinoki oil, castor oil or, phthalic acid esters, to contain one or more aliphatic polybasic acid ester, further, ethyl alcohol, or Isopuropa Roh Lumpur, or by addition of these mixtures, since the formulation without water , to increase the sealing effect between strength and flexibility of the film during film formation consisting mainly of nitrocellulose, adding antimycotic skin irritants and antipruritic After applying to the skin, the solvent is volatilized and a transparent or translucent film is formed on the skin to seal the affected area and prevent the spread of ringworm fungus from the affected area. To prevent infection to others. Further, the ODT effect (sealing effect) improves the transdermal absorbability of the antifungal agent, and a high bactericidal effect can be expected by sufficiently delivering the antifungal agent to the ringworm fungus layer below the stratum corneum.
In addition, since the dissolving agent itself exerts antifungal and bactericidal effects at the time of drug application, it exerts a bactericidal effect against superficial fungi and bacteria and promotes a therapeutic effect.
Furthermore, by coating the drug applied to the affected area with a film, the drug can be prevented from flowing out by bathing or showering, and the effect can be expected to last. Furthermore, the preparation after film formation flows out with water or warm water. Because there is very little, we do not pollute water of bathtub.
次に、本発明の好適な水虫治療用フィルム製剤の実施例を説明する。
第1の実施例の水虫治療用フィルム製剤の組成比を表1に示す
[表1]
[実施例1の組成比]
ニトロセルロース・・・・・・・5.0%
エチルアルコール・・・・・・63.0%
酢酸3−メチルブチル・・・・10.0%
アセトン・・・・・・・・・・・5.0%
サリチル酸・・・・・・・・・・5.0%
安息香酸・・・・・・・・・・10.0%
l−メントール・・・・・・・・1.0%
ひまし油・・・・・・・・・・・1.0%
合計 100.0%
Next, examples of suitable film preparations for treating athlete's foot of the present invention will be described.
Table 1 shows the composition ratio of the film preparation for athlete's foot treatment of the first example [Table 1].
[Composition ratio of Example 1]
Nitrocellulose ... 5.0%
Ethyl alcohol ... 63.0%
3-methylbutyl acetate: 10.0%
Acetone: 5.0%
Salicylic acid: 5.0%
Benzoic acid 10.0%
l-menthol ・ ・ ・ 1.0%
Castor oil ... 1.0%
Total 100.0%
[実施例1の調製方法]
実施例1の水虫治療用フィルム製剤は、前記の組成比になるように、次のような手段で調製する。なお、上記の実施例1の組成の重量%の合計は100%であり、製剤処方では実質的に水を含んでいない。
先ず、ニトロセルロースを酢酸3−メチルブチルに溶解させたのち、更にアセトンを添加して良く攪拌する。次に、この溶解液にエチルアルコールを加えて良く攪拌したのち、サリチル酸、安息香酸、l−メントール、更に、ひまし油と順次攪拌しつつ少量ずつ添加し、24時間室温放置して製造する。
ここで、皮膚に塗布した後溶剤が揮散し、透明或いは半透明のフィルムを皮膚上に形成させるには、ニトロセルロースは3〜20%、好ましくは、5〜12%であるが、ニトロセルロースが余り少ないとニトロセルロースによるフィルム形成が難しく、多すぎると、それだけ溶剤であるニトロセルロース、酢酸3−メチルブチル、アセトン等を多くすることになり、これらの溶剤が、例えば、肌荒れやかゆみや湿疹等の皮膚に悪影響を及ぼすので、ニトロセルロースの%を余り多くすることはできない。また、溶剤として、エチルアルコール50〜70%、好ましくは60〜65%、酢酸3−メチルブチルは8〜12%、好ましくは9〜11%、アセトンは3〜10%、好ましくは4〜6%程度が良いが、これらの配合比率は、少なすぎても多すぎてもニトロセルロースによるフィルムの形成が困難になり、多すぎると皮膚に悪影響を及ぼす。
[Preparation Method of Example 1]
The film preparation for athlete's foot treatment of Example 1 is prepared by the following means so as to achieve the above composition ratio. In addition, the sum total of the weight% of the composition of the above-mentioned Example 1 is 100%, and the pharmaceutical formulation does not substantially contain water.
First, after dissolving nitrocellulose in 3-methylbutyl acetate, acetone is further added and stirred well. Next, ethyl alcohol is added to the solution and stirred well. Then, salicylic acid, benzoic acid, l-menthol, and castor oil are added in small portions while sequentially stirring, and the mixture is allowed to stand at room temperature for 24 hours for production.
Here, in order to form a transparent or translucent film on the skin after application to the skin, the nitrocellulose is 3 to 20%, preferably 5 to 12%. If it is too small, film formation with nitrocellulose is difficult, and if it is too much, nitrocellulose, 3-methylbutyl acetate, acetone, etc., which are solvents, will increase, and these solvents may cause, for example, rough skin, itching and eczema. The% of nitrocellulose cannot be too high as it will have an adverse effect on the skin. Further, as a solvent, ethyl alcohol is 50 to 70%, preferably 60 to 65%, 3-methylbutyl acetate is 8 to 12%, preferably 9 to 11%, and acetone is about 3 to 10%, preferably about 4 to 6%. However, if the blending ratio is too small or too large, it becomes difficult to form a film with nitrocellulose, and if it is too large, the skin is adversely affected.
次に、第2の実施例の水虫治療用フィルム製剤の組成比を表3に示す
[表2]
[実施例2の組成比]
ニトロセルロース・・・・・・・10.0%
イソプロピルアルコール・・・・73.0%
酢酸イソブチル・・・・・・・・・5.0%
乳酸エステル・・・・・・・・・・5.0%
トルナフテート・・・・・・・・・2.0%
グリチルリチン酸・・・・・・・・1.0%
サリチル酸・・・・・・・・・・・2.0%
シソオイル・・・・・・・・・・・2.0%
合計 100.0%
Next, Table 3 shows the composition ratio of the film preparation for athlete's foot treatment of the second example [Table 2].
[Composition ratio of Example 2]
Nitrocellulose ... 10.0%
Isopropyl alcohol ... 73.0%
Isobutyl acetate: 5.0%
Lactic acid ester: 5.0%
Tolnaftate ... 2.0%
Glycyrrhizic acid 1.0%
Salicylic acid 2.0%
Perilla oil ... 2.0%
Total 100.0%
[実施例2の調製方法]
実施例2の水虫治療用フィルム製剤は、前記の組成比となるように、次のような手段で調製する。なお、上記の実施例2の組成の重量%の合計は100%であり、製剤処方では実質的に水を含んでいない。
先ず、ニトロセルロースを酢酸イソブチルに溶解させたのち、更に乳酸エステルを添加して良く攪拌する。次に、この溶液にイソプロピルアルコールを加えて、良く攪拌したのち、トルナフテート、グリチルリチン酸、サリチル酸、更にシソオイルと順次攪拌下に少量ずつ添加し、24時間室温放置して製造する。
ここで、皮膚に塗布したのち、溶解剤が揮散し、透明或いは半透明のフィルムを皮膚上に形成させるには、ニトロセルロースは3〜20%、好ましくは、5〜12%であるが、ニトロセルロースが余り少ないとニトロセルロースによるフィルム形成が難しく、多すぎると、それだけ溶剤であるイソプロピルアルコール、酢酸イソブチル、乳酸エステル等を多くすることになり、これらの溶剤が皮膚に悪影響を及ぼすので、ニトロセルロースの%を余り多くすることはできない。
また、溶剤として、イソプロピルアルコール50〜80%、好ましくは、65〜75%、酢酸イソブチルは3〜15%、好ましくは3〜15%、好ましくは、4〜10%、乳酸エステルは3〜10%、好ましくは、4〜8%程度が良いが、これらの配合比率は、少なすぎるとニトロセルロースによるフィルムの形成が困難になり、多すぎると皮膚に悪影響を及ぼす。
[Preparation Method of Example 2]
The film preparation for athlete's foot treatment of Example 2 is prepared by the following means so that the composition ratio is as described above. In addition, the sum total of the weight% of the composition of the above-mentioned Example 2 is 100%, and the pharmaceutical formulation does not substantially contain water.
First, after dissolving nitrocellulose in isobutyl acetate, a lactic acid ester is further added and stirred well. Next, after adding isopropyl alcohol to this solution and stirring well, tolnaftate, glycyrrhizic acid, salicylic acid, and perilla oil are added in small portions under stirring, and the mixture is allowed to stand at room temperature for 24 hours for production.
Here, the nitrocellulose is 3 to 20%, preferably 5 to 12% to form a transparent or translucent film on the skin after the dissolution agent is volatilized after being applied to the skin. If too little cellulose is formed, it is difficult to form a film with nitrocellulose. If too much cellulose is added, the amount of solvents such as isopropyl alcohol, isobutyl acetate, and lactic acid ester increases, and these solvents adversely affect the skin. % Cannot be too much.
Further, as a solvent, isopropyl alcohol is 50 to 80%, preferably 65 to 75%, isobutyl acetate is 3 to 15%, preferably 3 to 15%, preferably 4 to 10%, and lactic acid ester is 3 to 10%. However, it is preferably about 4 to 8%. However, if the blending ratio is too small, it becomes difficult to form a film with nitrocellulose, and if it is too large, the skin is adversely affected.
本発明の実施例1、及び、実施例2を、[水虫患部拭き取り培養試験]と[水虫治療試験]によって従来との作用効果の差異を検証するために、下記の比較例1〜5を用意した。
(1)参考例1:実施例1のフィルム形成成分のニトロセルロース、エチルアルコール、酢酸3−メチルブチル、アセトンを、実施例1と同じ配合比5.0:63:10:5にしたフィルム構成製剤
(2)比較例1:無処置(コントロール)
(3)比較例2:市販の水虫用軟膏で、E社製のサリチル酸、安息香酸含有の水虫用製剤(水虫に対する薬効成分は[実施例1]と同じで、[実施例1]のフィルムの被覆作用を検証するために用意した)。
(4)比較例3:実施例2の有効成分のみの製剤、即ち、被膜形成成分であるニトロセルロースと溶剤を含まない製剤処方で、[実施例2]と同じ配合比トルナフテート、グリチルリチン酸、サリチル酸、シソオイルを、2:1:2:2.とした製剤
(5)比較例4:市販の水虫用軟膏で、Y社製、有効成分トルナフテート、グリチルリチン酸、サリチル酸含有の水虫用製剤(水虫に対する薬効成分は[実施例2]と同じ)。
なお、比較例3、比較例4は、実施例1及び2、特に、実施例2の水虫治療作用を検証するために用意した。
In order to verify Example 1 and Example 2 of the present invention, the difference in action and effect from the conventional ones by the [wivesworm affected area wiping culture test] and [athlete's foot treatment test], the following comparative examples 1 to 5 are prepared. did.
(1) Reference Example 1: Film-forming preparation in which the film forming components of Example 1, nitrocellulose, ethyl alcohol, 3-methylbutyl acetate, and acetone were mixed at the same blending ratio as in Example 1, 5.0: 63: 10: 5 (2) Comparative Example 1: No treatment (control)
(3) Comparative Example 2: Commercial athlete ’s athlete's foot ointment containing salicylic acid and benzoic acid-containing athlete's foot preparations manufactured by company E (the medicinal components for athlete ’s foot are the same as in [Example 1]. Prepared to verify the covering action).
(4) Comparative Example 3: A preparation containing only the active ingredient of Example 2, that is, a formulation containing no nitrocellulose as a film-forming component and a solvent, and the same mixing ratio as in [Example 2] tolnaftate, glycyrrhizic acid, salicylic acid (5) Comparative Example 4: Commercially available athlete's foot ointment, manufactured by Y Company, containing active ingredients tolnaftate, glycyrrhizic acid, salicylic acid (medicinal effect against athlete's foot) Ingredients are the same as in [Example 2]).
In addition, the comparative example 3 and the comparative example 4 were prepared in order to verify the athlete's foot therapeutic action of Examples 1 and 2, especially Example 2.
[水虫患部拭き取り培養試験]
次に、前記の組成、及び調整方法で製造した実施例1の水虫治療用フィルム製剤と、参考例1、比較例1、及び、比較例2の市販製剤との作用・効果を以下の条件で水虫患部拭き取り培養試験で比較検証した。
(1)被検体
被検体としては、上記の実施例1、参考例1、比較例1,比較例2を用意した。
(2)被験者:水虫に罹患している成人ボランティア5名(男性35歳〜57歳、No1〜5)
(3)試験方法:試験開始前に被験者の白癬菌に罹患した右足底上部位を、精製水に含浸させた脱脂綿を用いて、直径約2cmの円形に拭き取り、シャーレに入れた培地上で培養し、これをコントロールである比較例1(無処置)とした。
次に、比較例2の製剤を、被験者の白癬菌に罹患した右足底下部に均一に塗布し、その6時間後に精製水を含浸させた脱脂綿を用いて、直径約2cmの円形に拭き取り、シャーレに入れた培地上で培養した。
さらに、参考例1の製剤を、被験者の白癬菌に罹患した左足底上部に均一に塗布し、同様に、その6時間後に精製水を含浸させた脱脂綿を用いて、直径約2cmの円形に拭き取り、シャーレに入れた培地上で培養した。
また、同時に、実施例1の製剤を白癬菌に罹患した左足底下部に塗布し、6時間後に前記と同様な方法で処理した。
この場合の皮膚に塗布した外的状態(6時間後)は、体温で溶解剤が揮散して半透明なフィルムが形成されているのが確認することができた。
[Wildworm wiping culture test]
Next, the action and effect of the film preparation for treating athlete's foot of Example 1 manufactured by the above-described composition and preparation method and the commercial preparations of Reference Example 1, Comparative Example 1, and Comparative Example 2 are as follows. Comparison was verified by wiping culture test for affected athlete's foot.
(1) Subject As the subject, the above Example 1, Reference Example 1, Comparative Example 1, and Comparative Example 2 were prepared.
(2) Subjects: 5 adult volunteers suffering from athlete's foot (men 35 to 57 years old, No 1 to 5)
(3) Test method: Before the start of the test, the right upper sole of the subject affected with ringworm fungus was wiped into a circular shape with a diameter of about 2 cm using absorbent cotton impregnated with purified water and cultured on a medium placed in a petri dish. This was designated as Comparative Example 1 (no treatment) as a control.
Next, the preparation of Comparative Example 2 was uniformly applied to the lower right foot sole affected by ringworm of the subject, and after 6 hours, wiped into a circular shape having a diameter of about 2 cm using absorbent cotton impregnated with purified water. The medium was cultured on the medium contained in the medium.
Furthermore, the preparation of Reference Example 1 was uniformly applied to the upper part of the left foot sole affected by ringworm of the subject, and similarly, wiped into a circular shape with a diameter of about 2 cm using absorbent cotton impregnated with purified water after 6 hours. The cells were cultured on a medium placed in a petri dish.
At the same time, the preparation of Example 1 was applied to the lower left sole affected by ringworm and treated in the same manner as described above after 6 hours.
In this case, the external state (after 6 hours) applied to the skin could be confirmed to have formed a translucent film by evaporating the dissolving agent at body temperature.
試験に使用した培地は、サブローブドウ糖寒天培地(SDA培地)を用い、培養はインキュベーターで25℃、10日間培養した。
各検体を10日間の培養後、下記の判定条件に基づいて観察・判定した。
判定条件:(1)シャーレ全面が白癬菌のコロニーで被覆・・・・・・+++(4点)
(2)シャーレの半分以上が白癬菌のコロニーで被覆・・・・++(3点)
(3)シャーレの10〜50%が白癬菌のコロニーで被覆・・・+(2点)
(4)シャーレの10%未満が白癬菌のコロニーで被覆・・・・±(1点)
(5)シャーレに全く白癬菌のコロニーが確認できない・・・・−(0点)
The medium used for the test was a Sabouraud glucose agar medium (SDA medium), and the culture was performed in an incubator at 25 ° C. for 10 days.
Each specimen was observed and judged based on the following judgment conditions after culturing for 10 days.
Judgment conditions: (1) The whole petri dish is covered with colonization of ringworm fungus .... ++++ (4 points)
(2) More than half of the petri dish is covered with colonization of ringworm fungus ... ++ (3 points)
(3) 10-50% of the petri dish covered with colonies of ringworm fungus ... + (2 points)
(4) Less than 10% of the petri dish is covered with colonies of ringworm bacteria ... ± (1 point)
(5) No ringworm colonies can be confirmed in the petri dish ...-(0 points)
(4)試験結果
前記の試験結果を、次の[表3]に示す。
[表3]
(4) Test results The test results are shown in the following [Table 3].
[Table 3]
前記の[表2]から判ることは、無処置群(コントロール)としての比較例1は、被験者5名全員の採取サンプルに白癬菌のコロニーがシャーレ全面に確認され、その評価点数の平均値は3.6と非常に高い結果を示すことである。
また、比較例2の製剤は、±〜++のコロニーの程度の差が認められ、比較例1(無処置)に比較して約50%の抑制が認められるものの、実施例1に比較するとコロニーの評価点数が1.8点であった。
これに対して、実施例1と参考例1の製剤は、シャーレ上に全く白癬菌のコロニーは認められず、従って、評価点数の平均値も0であった。このことは、実施例1と参考例の製剤は、共に、フィルムの形成により、比較例1、比較例2に比較して、白癬菌に罹患した患部を被覆するODT効果(密封効果)によって、患部からの白癬菌の離脱・拡散を防止することが推察される。
It can be seen from the above [Table 2] that in Comparative Example 1 as the untreated group (control), colonies of ringworms were confirmed on the entire petri dish in the collected samples of all five subjects, and the average value of the evaluation scores was It shows a very high result of 3.6.
In addition, the preparation of Comparative Example 2 shows a difference in the degree of colony of ± to ++, and about 50% of the inhibition is recognized as compared with Comparative Example 1 (no treatment). The evaluation score was 1.8 points.
On the other hand, in the preparations of Example 1 and Reference Example 1, no colony of ringworms was found on the petri dish, and thus the average score was 0. This is because both the preparations of Example 1 and the reference example have ODT effect (sealing effect) covering the affected area affected by ringworm as compared with Comparative Example 1 and Comparative Example 2 due to film formation. It is presumed to prevent withdrawal and spread of ringworm bacteria from the affected area.
[水虫治療試験]
次に、被検体として、前記の組成及び調製方法で製造した実施例1,実施例2の水虫治療用フィルム製剤と、比較例1の無処置、比較例3([実施例2]のフィルム形成成分無し)、比較例4([実施例2]に同等で、フィルム形成成分無しの市販製剤)との治療効果を以下の条件下で比較検証した。
(1)被検体として、実施例1、実施例2、比較例1,比較例3、比較例4を用意した。
(2)被験者:水虫に罹患している成人男性ボランティア15名(40歳〜57歳)
(3)試験方法:1群3名とし、試験開始前に各群の被験者の白癬菌に罹患した右足底部を精製水を含浸させた脱脂綿を用いて直径2cmの円形に拭き取り、シャーレに入れた培地上で培養し、これを試験開始前の白癬菌罹患強度の評価判定とした。
次に、各被験者の水虫罹患部位である右足底部位全体に各被検体を入浴後30分に均一に塗布した。この塗布行為を、35日間にわたって実施した。この期間中の7日目、14日目、21日目、28日目及び35日目の入浴後30分の各薬剤塗布前に患部(右足底部)を精製水を含浸させた脱脂綿を用いて直径2cmの円形に拭き取り、シャーレ上の培地にて培養した。
試験に使用した培地は、サブローブドウ糖寒天培地(SDA培地)を用い、培養はインキュベーターで25℃の条件で10日間培養した。
そして、培養した各検体を下記の判定基準に基づいて観察、判定した。
判定基準:(1)シャーレ全面が白癬菌のコロニーで被覆・・・・・・+++(4点)
(2)シャーレの半分以上が白癬菌のコロニーで被覆・・・・++(3点)
(3)シャーレの10〜50%が白癬菌のコロニーで被覆・・・+(2点)
(4)シャーレの10%未満が白癬菌のコロニーで被覆・・・・±(1点)
(5)シャーレに全く白癬菌のコロニーが確認されない・・・・−(0点)
[Squamworm treatment test]
Next, as test specimens, the film preparations for athlete's foot treatment of Examples 1 and 2 manufactured by the above-described composition and preparation method, no treatment of Comparative Example 1, and Comparative Example 3 (film formation of [Example 2]) Ingredients) and Comparative Example 4 (commercially available preparation with no film-forming component equivalent to [Example 2]) were compared and verified under the following conditions.
(1) Example 1, Example 2, Comparative Example 1, Comparative Example 3, and Comparative Example 4 were prepared as specimens.
(2) Subjects: 15 adult male volunteers suffering from athlete's foot (40 to 57 years old)
(3) Test method: 3 people per group, and before the start of the test, the right foot bottom part of each group of test subjects affected by ringworm bacteria was wiped into a 2 cm diameter circle using absorbent cotton impregnated with purified water and placed in a petri dish. Cultivation was carried out on a medium, and this was used as an evaluation judgment of the intensity of ringworm fungus before the start of the test.
Next, each subject was uniformly applied 30 minutes after bathing on the entire right foot site, which was the affected part of athlete's foot. This application action was carried out for 35 days. Using absorbent cotton in which the affected area (right sole) was impregnated with purified water 30 minutes before each drug application 30 minutes after bathing on the 7th, 14th, 21st, 28th and 35th days during this period It was wiped off in a circle with a diameter of 2 cm and cultured in a medium on a petri dish.
The medium used for the test was a Sabouraud glucose agar medium (SDA medium), and the culture was performed in an incubator at 25 ° C. for 10 days.
Each cultured specimen was observed and determined based on the following criteria.
Judgment criteria: (1) The petri dish is entirely covered with colonization of ringworm fungus .... ++ (4 points)
(2) More than half of the petri dish is covered with colonies of ringworm fungus .... ++ (3 points)
(3) 10-50% of petri dish is covered with colonization of ringworm fungus ... + (2 points)
(4) Less than 10% of the petri dish is covered with colonies of ringworm fungus ... ± (1 point)
(5) There is no colonization of ringworm fungus in the petri dish ...-(0 points)
(4)試験結果
前記の試験結果を、次の[表4]に示す。
[表4]
(4) Test results The test results are shown in the following [Table 4].
[Table 4]
前記の[表4]から判ることは、無処置群(コントロール)としての比較例1は、被験者3名全員の採取サンプルから試験開始前と同様に試験開始後の35日目においても白癬菌のコロニーがシャーレ全面を被覆する状態で観察され、その評価点数の平均値は4.0と非常に高い値を示した。
実施例2から被膜形成成分を処方除去した比較例3では、経日的に白癬菌に対する抑制効果が認められ、試験開始後28日目で評価平均点数は2.3、35日目で1.7を記録したが、完全に菌を抑制できなかった。市販薬である比較例4も比較例3と同様に、経日的に白癬菌を抑制する傾向を示し、試験最終日の35日目には評価平均点数が2.0を示した。
これに対して、実施例1、及び、実施例2は、比較例3及び4と同様に白癬菌を経日的に抑制したが、その抑制強度と抑制速度において前2者を遥かに凌ぐものであり、試験開始28日目には評価平均点数は0.3となり最終の35日目には完全に白癬菌を抑制し、35日後の評価平均点数は0.0であった。
以上の結果から、本発明に基づく水虫用フィルム製剤の実施例は被膜を塗布した患部に形成することによって、有効成分の脱落・消失(ソックス、スリッパ等の皮膚接触による物理的刺激による)を防止し、更に患部のODT効果(密封効果)によって、有効成分の経皮吸収性が格段に高められた結果、より多くの有効成分がより早く白癬菌が生息する角質層に供給された結果、非常に効率的で高い殺菌効果が得られたものと考えられた。
It can be seen from the above [Table 4] that Comparative Example 1 as an untreated group (control) shows that the trichophytic fungi are also collected on the 35th day after the start of the test from the collected samples of all three subjects. A colony was observed in a state of covering the entire surface of the petri dish, and the average value of the evaluation score was 4.0, which was a very high value.
In Comparative Example 3 in which the film-forming component was removed from Example 2, an inhibitory effect against ringworm was observed over time, and the evaluation average score was 2.3 on the 28th day after the start of the test and 1. on the 35th day. 7 was recorded, but the bacteria could not be completely suppressed. As in Comparative Example 3, Comparative Example 4 which is a commercially available drug also showed a tendency to suppress ringworms over time, and the evaluation average score was 2.0 on the 35th day of the final test day.
On the other hand, Example 1 and Example 2 suppressed ringworm fungus daily, similar to Comparative Examples 3 and 4, but far exceeded the former two in their suppression strength and speed. On the 28th day from the start of the test, the evaluation average score was 0.3, and on the final 35th day, the ringworm was completely suppressed, and the evaluation average score after 35 days was 0.0.
From the above results, the embodiment of the film preparation for athlete's foot according to the present invention prevents the active ingredient from falling off or disappearing (due to physical irritation due to skin contact with socks, slippers, etc.) by forming it on the affected area to which the film is applied. As a result of the ODT effect (sealing effect) of the affected area, the percutaneous absorbability of the active ingredient was remarkably improved, and as a result, more active ingredient was supplied to the stratum corneum where the ringworm bacteria inhabit faster. It was thought that the highly effective and high bactericidal effect was obtained.
以上の実験の結果から、本発明に基づく水虫用フィルム治療用製剤の実施例は、ニトロセルロースを、酢酸3−メチルブチル、酢酸エチル、酢酸イソブチル、乳酸エステル、アセトン、及び/または、これらの混合物の溶解剤に溶解し、更に、エチルアルコールを添加した基剤に、水虫の外用薬を添加したものであるので、皮膚に塗布した後溶剤が揮散し、透明或いは半透明のフィルムを皮膚上に形成することにより患部を密封し、真菌の患部からの拡散を予防することによって他者への感染を防ぐことが可能となる。更に、ODT効果(密封効果)によって抗真菌薬の経皮吸収性が向上し、皮膚角質層下部の真菌生息層に薬剤が浸透することによって白癬菌に対する殺菌効果が増強されることが実証された。
また、溶解剤(酢酸3−メチルブチル、酢酸エチル、酢酸イソブチル、乳酸エステル、アセトン、エチルアルコール)自体が殺菌作用及び抗真菌作用を有するために、患部の皮膚に塗布する段階で表在性の雑菌及び真菌に対して殺菌及び抗真菌作用を発揮することも判明した。
From the results of the above experiments, examples of the preparation for athlete's foot film treatment according to the present invention include nitrocellulose, 3-methylbutyl acetate, ethyl acetate, isobutyl acetate, lactate ester, acetone, and / or a mixture thereof. Since it is dissolved in a solubilizing agent and further added with an external preparation for athlete's foot to a base added with ethyl alcohol, the solvent evaporates after application to the skin, forming a transparent or translucent film on the skin By doing so, it is possible to seal the affected area and prevent the infection from occurring by preventing the spread of the fungus from the affected area. Furthermore, the ODT effect (sealing effect) has improved the percutaneous absorption of antifungal drugs, and it has been demonstrated that the bactericidal effect against ringworm fungi is enhanced by the penetration of the drug into the fungal layer below the stratum corneum. .
In addition, since the dissolving agent (3-methylbutyl acetate, ethyl acetate, isobutyl acetate, lactate ester, acetone, ethyl alcohol) itself has a bactericidal action and an antifungal action, it is a superficial germ at the stage of application to the affected skin. It has also been found to exert bactericidal and antifungal effects against fungi.
なお、本発明の特徴を損なうものでなければ、上述した実施例に限定されるものでないことは勿論であり、例えば、本実施例では、抗真菌薬の外用薬としてサリチル酸と安息香酸を用いたが、このほか塩酸ブテナフィン、塩酸テルビナフィン、塩酸ネチコナゾール、塩酸アモロルフィン、硝酸エコナゾール、スティコプスエキス、トルナフテート、ピロールニトリン、クロトリマゾール、蝋梅油、クエン酸、酢酸、木酢液、竹酢液を用いてもよく、これらの一種類以上を適宜組み合わせてもよい。同様に、本実施例では、角質を溶解して有効薬物の治療効果を促進する角質溶解剤として、サリチル酸、安息香酸を用いたが、この外に尿素を用いてもよく、これらの一種類以上を適宜組み合わせてもよい。同様に、本実施例では、患部のかゆみを抑制する外用薬として、l−メントールを用いたが、この他に、グリチルリチン酸、グリチルリチン酸ナトリウム、グリチルレチン酸、リドカイン、キシロカイン、クロタミトン、カンフル、ハッカ油を用いてもよく、これらの一種類以上を適宜組み合わせてもよい。同様に、本実施例では、前記溶解剤の中には、膜形成時の膜の強度・柔軟性と密封効果を高めるために、ひまし油を用いたが、シソオイル、ゴマ油、エゴマ油、オリーブ油、馬油、ヒノキオイル、フタル酸エステル、脂肪族多塩基酸エステルでもよく、これらを適宜組み合わせたものでもよい。 Of course, the present invention is not limited to the above-described examples as long as the characteristics of the present invention are not impaired. For example, in this example, salicylic acid and benzoic acid were used as external preparations for antifungal drugs. In addition, butenafine hydrochloride, terbinafine hydrochloride, neticonazole hydrochloride, amorolfine hydrochloride, econazole nitrate, stipops extract, tolnaftate, pyrrolnitrin, clotrimazole, bran oil, citric acid, acetic acid, wood vinegar, bamboo vinegar One or more of these may be combined as appropriate. Similarly, in this example, salicylic acid and benzoic acid were used as the keratolytic agent that dissolves the keratin and promotes the therapeutic effect of the active drug, but urea may be used in addition to this, and one or more of these may be used. May be combined as appropriate. Similarly, in this example, l-menthol was used as an external medicine for suppressing itching of the affected area, but besides this, glycyrrhizic acid, sodium glycyrrhizinate, glycyrrhetinic acid, lidocaine, xylocaine, crotamiton, camphor, mint oil Or one or more of these may be combined as appropriate. Similarly, in this example, castor oil was used as the solubilizer in order to enhance the strength / flexibility of the film during film formation and the sealing effect, but perilla oil, sesame oil, egoma oil, olive oil, horse Oil, hinoki oil, phthalic acid ester, aliphatic polybasic acid ester, or a combination of these may be used.
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005254415A JP5010125B2 (en) | 2005-09-02 | 2005-09-02 | Film preparation for athlete's foot treatment |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005254415A JP5010125B2 (en) | 2005-09-02 | 2005-09-02 | Film preparation for athlete's foot treatment |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007063227A JP2007063227A (en) | 2007-03-15 |
JP5010125B2 true JP5010125B2 (en) | 2012-08-29 |
Family
ID=37925814
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005254415A Expired - Fee Related JP5010125B2 (en) | 2005-09-02 | 2005-09-02 | Film preparation for athlete's foot treatment |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5010125B2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011044008A1 (en) * | 2009-10-08 | 2011-04-14 | Schering-Plough Healthcare Products, Inc. | Low ether composition and delivery apparatus |
JP5951084B1 (en) | 2015-07-24 | 2016-07-13 | 司郎 吉崎 | Dermatomycosis treatment |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4227677B2 (en) * | 1996-12-10 | 2009-02-18 | 杏林製薬株式会社 | Film-forming antifungal composition |
US6231875B1 (en) * | 1998-03-31 | 2001-05-15 | Johnson & Johnson Consumer Companies, Inc. | Acidified composition for topical treatment of nail and skin conditions |
PL357111A1 (en) * | 2000-02-16 | 2004-07-12 | Bentley Pharmaceuticals, Inc. | Pharmaceutical composition |
DE10011081A1 (en) * | 2000-03-09 | 2001-09-13 | Aventis Pharma Gmbh | Lacquer formulation for treating and preventing onychomycosis, comprising combination of systemic and topical antimycotic agents in film-forming polymer base |
-
2005
- 2005-09-02 JP JP2005254415A patent/JP5010125B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2007063227A (en) | 2007-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10195239B2 (en) | Extract of Trigonella foenum-graecum | |
JP6360267B2 (en) | Antifungal composition for the treatment of skin and nails | |
WO2009048841A1 (en) | Antifungal treatment of nails | |
US9439972B2 (en) | Antifungal serum | |
JP6122035B2 (en) | Antifungal composition for the treatment of skin and nails | |
EA037323B1 (en) | Dermatological composition based on algae and olive leaf extracts | |
JP5010125B2 (en) | Film preparation for athlete's foot treatment | |
AU2017272269B2 (en) | Excipient system for topical delivery of pharmaceutical agents | |
EP3378475B1 (en) | Composition and kit for the use in the prevention of recurrent onychomycosis | |
EP2692332B1 (en) | Composition for the treatment of callus, corns and psoriasis | |
Bhapkar et al. | Topic name–nail lacquers in nail diseases | |
WO2017051293A1 (en) | Antifungal topical composition for the use in the treatment of onychomycosis | |
Berg et al. | Fungal skin infections in children: new developments and treatments | |
JP7399954B2 (en) | Hypoallergenic composition for topical treatment of skin and nail disorders caused by viruses and fungi | |
TWI284523B (en) | Sterilized cotton ball (swab) or spraying device with anesthetized pain relieving function | |
CN106236756B (en) | A kind of chlorophyll ointment and preparation method thereof that mosquito control is bitten | |
RU2657807C1 (en) | Method for treatment of oral candidiasis in patients with removable prosthetic restorations by solkoseril and chophytol drug products | |
WO2024091410A1 (en) | Composition for promoting moisture absorption and retention in skin and method of preparing the composition | |
JPH09194373A (en) | Medicine for external use for athlete's foot | |
JPH09194372A (en) | Medicine for external use for athlete's foot | |
JPS61186318A (en) | External preparation for athlet's foot | |
AU2008227064A1 (en) | Compositions for the treatment of a skin condition and methods for use therein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080806 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110902 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111025 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120523 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120601 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 5010125 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150608 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |